Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination.
TAK-003
dengue
efficacy
immunogenicity
persistence
safety
vaccine
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
04 05 2022
04 05 2022
Historique:
received:
08
10
2020
accepted:
10
12
2020
pubmed:
16
12
2020
medline:
10
5
2022
entrez:
15
12
2020
Statut:
ppublish
Résumé
Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. Children (20 099, 4-16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are under surveillance to detect dengue by serotype-specific RT-PCR. Cumulative efficacy against dengue approximately 27 months since first dose was 72.7% (95% confidence interval [CI], 67.1%-77.3%), including 67.0% (95% CI, 53.6%-76.5%) in dengue-naive and 89.2% (95% CI, 82.4%-93.3%) against hospitalized dengue. In the second year, decline in efficacy was observed (56.2%; 95% CI, 42.3%-66.8%) with the largest decline in 4-5 year olds (24.5%; 95% CI, -34.2% to 57.5%); efficacy was 60.6% (95% CI, 43.8%-72.4%) in 6-11 year and 71.2% (95% CI, 41.0%-85.9%) in 12-16 year age groups. As TAK-003 efficacy varies by serotype, changes in serotype dominance partially contributed to efficacy differences in year-by-year analysis. No related serious adverse events occurred during the second year. TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be important to see if efficacy stabilizes or declines further.Clinical Trials Registration. NCT02747927.Takeda's tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after completing vaccination with some decline in efficacy during the second year in 4-16 year olds in dengue-endemic countries.
Sections du résumé
BACKGROUND
Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update.
METHODS
Children (20 099, 4-16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are under surveillance to detect dengue by serotype-specific RT-PCR.
RESULTS
Cumulative efficacy against dengue approximately 27 months since first dose was 72.7% (95% confidence interval [CI], 67.1%-77.3%), including 67.0% (95% CI, 53.6%-76.5%) in dengue-naive and 89.2% (95% CI, 82.4%-93.3%) against hospitalized dengue. In the second year, decline in efficacy was observed (56.2%; 95% CI, 42.3%-66.8%) with the largest decline in 4-5 year olds (24.5%; 95% CI, -34.2% to 57.5%); efficacy was 60.6% (95% CI, 43.8%-72.4%) in 6-11 year and 71.2% (95% CI, 41.0%-85.9%) in 12-16 year age groups. As TAK-003 efficacy varies by serotype, changes in serotype dominance partially contributed to efficacy differences in year-by-year analysis. No related serious adverse events occurred during the second year.
CONCLUSIONS
TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be important to see if efficacy stabilizes or declines further.Clinical Trials Registration. NCT02747927.Takeda's tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after completing vaccination with some decline in efficacy during the second year in 4-16 year olds in dengue-endemic countries.
Identifiants
pubmed: 33319249
pii: 6034203
doi: 10.1093/infdis/jiaa761
pmc: PMC9071282
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Dengue Vaccines
0
Vaccines, Attenuated
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1521-1532Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
N Engl J Med. 2019 Nov 21;381(21):2009-2019
pubmed: 31693803
J Infect Dis. 2015 Nov 15;212(10):1618-28
pubmed: 25943203
Vaccine. 2020 Apr 23;38(19):3531-3536
pubmed: 32204943
Vaccine. 2018 Jun 22;36(27):3976-3983
pubmed: 29789238
PLoS Negl Trop Dis. 2013 May 30;7(5):e2243
pubmed: 23738026
Lancet Infect Dis. 2014 Sep;14(9):830-8
pubmed: 25087476
N Engl J Med. 2015 Sep 24;373(13):1195-206
pubmed: 26214039
PLoS Negl Trop Dis. 2019 Mar 28;13(3):e0007213
pubmed: 30921321
Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16
pubmed: 21079655
Nature. 2013 Apr 25;496(7446):504-7
pubmed: 23563266
J Infect Dis. 2015 Oct 1;212(7):1032-41
pubmed: 25791116
Vaccine. 2015 Nov 17;33(46):6351-9
pubmed: 26384447
J Infect Dis. 2016 May 15;213(10):1562-72
pubmed: 26704612
Hum Vaccin Immunother. 2020 Oct 2;16(10):2456-2464
pubmed: 32119591
N Engl J Med. 2018 Jul 26;379(4):327-340
pubmed: 29897841
Lancet. 2020 May 2;395(10234):1434-1443
pubmed: 32197107
Lancet Infect Dis. 2017 Jun;17(6):615-625
pubmed: 28365225
Lancet. 2020 May 2;395(10234):1423-1433
pubmed: 32197105
Lancet Infect Dis. 2018 Feb;18(2):162-170
pubmed: 29122463